{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T02:06:15Z","timestamp":1790647575701,"version":"4.1.0"},"reference-count":37,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2018,3,1]],"date-time":"2018-03-01T00:00:00Z","timestamp":1519862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2018,3]]},"DOI":"10.1016\/j.ygyno.2018.01.025","type":"journal-article","created":{"date-parts":[[2018,2,2]],"date-time":"2018-02-02T00:14:38Z","timestamp":1517530478000},"page":"576-584","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"title":["ROR1 and ROR2 play distinct and opposing roles in endometrial cancer"],"prefix":"10.1016","volume":"148","author":[{"given":"C.E.","family":"Henry","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Llamosas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Daniels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Coopes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.E.","family":"Ford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9484","key":"10.1016\/j.ygyno.2018.01.025_bb0005","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S0140-6736(05)67063-8","article-title":"Endometrial cancer","volume":"366","author":"Amant","year":"2005","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.ygyno.2018.01.025_bb0010","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.ygyno.2014.06.003","article-title":"Endometrial cancer: a review and current management strategies: part II","volume":"134","author":"Group SGOCPECW","year":"2014","journal-title":"Gynecol. Oncol."},{"issue":"2","key":"10.1016\/j.ygyno.2018.01.025_bb0015","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1590\/S1679-45082016AO3678","article-title":"The destruction complex of beta-catenin in colorectal carcinoma and colonic adenoma","volume":"14","author":"Bourroul","year":"2016","journal-title":"Einstein"},{"issue":"5307","key":"10.1016\/j.ygyno.2018.01.025_bb0020","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1126\/science.275.5307.1787","article-title":"Activation of \u03b2-catenin-Tcf signaling in colon cancer by mutations in \u03b2-catenin or APC","volume":"275","author":"Morin","year":"1997","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.ygyno.2018.01.025_bb0025","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s007950200001","article-title":"Mutation of beta-catenin gene in endometrial cancer but not in associated hyperplasia","volume":"35","author":"Ashihara","year":"2002","journal-title":"Med. Electron Microsc."},{"issue":"2","key":"10.1016\/j.ygyno.2018.01.025_bb0030","first-page":"323","article-title":"Mutational analysis of the CTNNB1 (beta-catenin) gene in human endometrial cancer: frequent mutations at codon 34 that cause nuclear accumulation","volume":"7","author":"Ikeda","year":"2000","journal-title":"Oncol. Rep."},{"issue":"7","key":"10.1016\/j.ygyno.2018.01.025_bb0035","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1038\/modpathol.2017.15","article-title":"CTNNB1 (beta-catenin) mutation identifies low grade, early stage endometrial cancer patients at increased risk of recurrence","volume":"30","author":"Kurnit","year":"2017","journal-title":"Mod. Pathol."},{"issue":"52","key":"10.1016\/j.ygyno.2018.01.025_bb0040","doi-asserted-by":"crossref","first-page":"7981","DOI":"10.1038\/sj.onc.1205924","article-title":"Abnormalities of the APC\/beta-catenin pathway in endometrial cancer","volume":"21","author":"Moreno-Bueno","year":"2002","journal-title":"Oncogene"},{"issue":"3","key":"10.1016\/j.ygyno.2018.01.025_bb0045","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.ygyno.2012.05.012","article-title":"Improved risk assessment of endometrial cancer by combined analysis of MSI, PI3K-AKT, Wnt\/beta-catenin and P53 pathway activation","volume":"126","author":"Nout","year":"2012","journal-title":"Gynecol. Oncol."},{"issue":"3","key":"10.1016\/j.ygyno.2018.01.025_bb0050","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1097\/IGC.0000000000000626","article-title":"Expression of PTEN and beta-catenin and their relationship with clinicopathological and prognostic factors in endometrioid type endometrial cancer","volume":"26","author":"Sal","year":"2016","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"1","key":"10.1016\/j.ygyno.2018.01.025_bb0055","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1002\/path.4160","article-title":"Alterations in Wnt-beta-catenin and Pten signalling play distinct roles in endometrial cancer initiation and progression","volume":"230","author":"van der Zee","year":"2013","journal-title":"J. Pathol."},{"issue":"18","key":"10.1016\/j.ygyno.2018.01.025_bb0060","doi-asserted-by":"crossref","first-page":"5784","DOI":"10.1158\/1078-0432.CCR-09-0814","article-title":"Progesterone inhibition of Wnt\/beta-catenin signaling in normal endometrium and endometrial cancer","volume":"15","author":"Wang","year":"2009","journal-title":"Clin. Cancer Res."},{"issue":"7","key":"10.1016\/j.ygyno.2018.01.025_bb0065","doi-asserted-by":"crossref","first-page":"674","DOI":"10.18632\/oncotarget.201","article-title":"Wnt\/beta-catenin and sex hormone signaling in endometrial homeostasis and cancer","volume":"1","author":"Wang","year":"2010","journal-title":"Oncotarget"},{"issue":"2","key":"10.1016\/j.ygyno.2018.01.025_bb0070","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.ygyno.2014.06.004","article-title":"The non-canonical Wnt ligand, Wnt5a, is upregulated and associated with epithelial to mesenchymal transition in epithelial ovarian cancer","volume":"134","author":"Ford","year":"2014","journal-title":"Gynecol. Oncol."},{"issue":"37","key":"10.1016\/j.ygyno.2018.01.025_bb0075","doi-asserted-by":"crossref","first-page":"40310","DOI":"10.18632\/oncotarget.5643","article-title":"Targeting the ROR1 and ROR2 receptors in epithelial ovarian cancer inhibits cell migration and invasion","volume":"6","author":"Henry","year":"2015","journal-title":"Oncotarget"},{"issue":"5","key":"10.1016\/j.ygyno.2018.01.025_bb0080","article-title":"Migration and invasion is inhibited by silencing ROR1 and ROR2 in chemoresistant ovarian cancer","volume":"5","author":"Henry","year":"2016","journal-title":"Oncogene"},{"issue":"1","key":"10.1016\/j.ygyno.2018.01.025_bb0085","first-page":"856","article-title":"Up-regulation of ROR2 is associated with unfavorable prognosis and tumor progression in cervical cancer","volume":"8","author":"Sun","year":"2015","journal-title":"Int. J. Clin. Exp. Pathol."},{"key":"10.1016\/j.ygyno.2018.01.025_bb0090","article-title":"Adipocytes sustain pancreatic cancer progression through a non-canonical WNT paracrine network inducing ROR2 nuclear shuttling","author":"Carbone","year":"2017","journal-title":"Int. J. Obes."},{"issue":"3","key":"10.1016\/j.ygyno.2018.01.025_bb0095","first-page":"122","article-title":"ROR1 as a novel therapeutic target for EGFR-mutant non-small-cell lung cancer patients with the EGFR T790M mutation","volume":"3","author":"Karachaliou","year":"2014","journal-title":"Transl. Lung Cancer Res."},{"key":"10.1016\/j.ygyno.2018.01.025_bb0100","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1186\/s12885-016-2576-7","article-title":"ROR2 is epigenetically inactivated in the early stages of colorectal neoplasia and is associated with proliferation and migration","volume":"16","author":"Ma","year":"2016","journal-title":"BMC Cancer"},{"issue":"8","key":"10.1016\/j.ygyno.2018.01.025_bb0105","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1038\/bjc.1997.195","article-title":"Expression and hormone regulation of Wnt2, 3, 4, 5a, 7a, 7b and 10b in normal human endometrium and endometrial carcinoma","volume":"75","author":"Bui","year":"1997","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ygyno.2018.01.025_bb0110","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s11658-016-0003-3","article-title":"WNT5A-ROR2 is induced by inflammatory mediators and is involved in the migration of human ovarian cancer cell line SKOV-3","volume":"21","author":"Arabzadeh","year":"2016","journal-title":"Cell. Mol. Biol. Lett."},{"issue":"3","key":"10.1016\/j.ygyno.2018.01.025_bb0115","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.tranon.2017.01.014","article-title":"Distinct patterns of stromal and tumor expression of ROR1 and ROR2 in histological subtypes of epithelial ovarian cancer","volume":"10","author":"Henry","year":"2017","journal-title":"Transl. Oncol."},{"issue":"6","key":"10.1016\/j.ygyno.2018.01.025_bb0120","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1139\/bcb-2016-0216","article-title":"Wnt5A regulates the expression of ROR2 tyrosine kinase receptor in ovarian cancer cells","volume":"95","author":"Hossein","year":"2017","journal-title":"Biochem. Cell Biol."},{"key":"10.1016\/j.ygyno.2018.01.025_bb0125","doi-asserted-by":"crossref","first-page":"5811","DOI":"10.1038\/srep05811","article-title":"ROR1 expression correlated with poor clinical outcome in human ovarian cancer","volume":"4","author":"Zhang","year":"2014","journal-title":"Sci. Rep."},{"issue":"48","key":"10.1016\/j.ygyno.2018.01.025_bb0130","doi-asserted-by":"crossref","first-page":"17266","DOI":"10.1073\/pnas.1419599111","article-title":"Ovarian cancer stem cells express ROR1, which can be targeted for anti-cancer-stem-cell therapy","volume":"111","author":"Zhang","year":"2014","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"5","key":"10.1016\/j.ygyno.2018.01.025_bb0135","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1007\/s00428-016-1911-3","article-title":"Expression of ROR1 has prognostic significance in triple negative breast cancer","volume":"468","author":"Chien","year":"2016","journal-title":"Virchows Arch."},{"issue":"1","key":"10.1016\/j.ygyno.2018.01.025_bb0140","doi-asserted-by":"crossref","first-page":"181","DOI":"10.3892\/ijo.2015.3241","article-title":"miR-382 inhibits migration and invasion by targeting ROR1 through regulating EMT in ovarian cancer","volume":"48","author":"Tan","year":"2016","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.ygyno.2018.01.025_bb0145","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/nature11412","article-title":"Comprehensive molecular portraits of human breast tumours","volume":"490","author":"The Cancer Genome Atlas Network","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.ygyno.2018.01.025_bb0150","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/nature12113","article-title":"Integrated genomic characterization of endometrial carcinoma","volume":"497","author":"Levine","year":"2013","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.ygyno.2018.01.025_bb0155","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.3892\/ol.2017.6386","article-title":"High expression levels of Wnt5a and Ror2 in laryngeal squamous cell carcinoma are associated with poor prognosis","volume":"14","author":"Zhang","year":"2017","journal-title":"Oncol. Lett."},{"issue":"3","key":"10.1016\/j.ygyno.2018.01.025_bb0160","article-title":"ROR1 is expressed in human breast cancer and associated with enhanced tumor-cell growth","volume":"7","author":"Zhang","year":"2012","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.ygyno.2018.01.025_bb0165","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s00428-003-0947-3","article-title":"Molecular genetic pathways in various types of endometrial carcinoma: from a phenotypical to a molecular-based classification","volume":"444","author":"Lax","year":"2004","journal-title":"Virchows Arch."},{"key":"10.1016\/j.ygyno.2018.01.025_bb0170","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.imlet.2017.11.010","article-title":"Inhibition of tumor growth by mouse ROR1 specific antibody in a syngeneic mouse tumor model","volume":"193","author":"Hassannia","year":"2018","journal-title":"Immunol. Lett."},{"issue":"55","key":"10.1016\/j.ygyno.2018.01.025_bb0175","doi-asserted-by":"crossref","first-page":"94210","DOI":"10.18632\/oncotarget.21618","article-title":"Antitumor activity of a newly developed monoclonal antibody against ROR1 in ovarian cancer cells","volume":"8","author":"Yin","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.ygyno.2018.01.025_bb0180","doi-asserted-by":"crossref","first-page":"S167","DOI":"10.1016\/j.clml.2015.02.010","article-title":"Pre-clinical specificity and safety of UC-961, a first-in-class monoclonal antibody targeting ROR1","volume":"15","author":"Choi","year":"2015","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"issue":"11","key":"10.1016\/j.ygyno.2018.01.025_bb0185","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1038\/onc.2016.304","article-title":"Wnt signaling in cancer","volume":"36","author":"Zhan","year":"2017","journal-title":"Oncogene"}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825818300647?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825818300647?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,10,10]],"date-time":"2019-10-10T04:55:18Z","timestamp":1570683318000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825818300647"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3]]},"references-count":37,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,3]]}},"alternative-id":["S0090825818300647"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2018.01.025","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2018,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"ROR1 and ROR2 play distinct and opposing roles in endometrial cancer","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2018.01.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}